Arca
Skip to content
Tools
Tools

Gastroparesis

Drug research and approvals for gastroparesis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 44 studies of gastroparesis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.

  • Recruiting worldwide: 44
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 44 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 4

Phase 2 12 of 24

Phase 1 or earlier 7

How its trials ended

291 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 87 whose ending is known, 28% met their primary endpoint, 6% missed it and 67% stopped early.

  • Ongoing9332%
  • Completed, result not reported8429%
  • Stopped: other or unclear3612%
  • Status unknown279%
  • Met its primary endpoint248%
  • Stopped: enrollment or feasibility114%
  • Stopped: sponsor or business decision93%
  • Missed its primary endpoint52%
  • Stopped: lack of efficacy21%

Trials authorized in Canada

Newest first; search them all in Canada trials
Oct 21, 2024Primers - a phase II, prospective, randomized, double-blinded, parallel group, placebo-controlled investigation of metoclopramide effects on full-stomach rates…MetoclopramideThunder Bay Regional Health Research InstitutePending
Jul 24, 2019Open-label extension study of relamorelin for the treatment of diabetic gastroparesisRelamorelinAbbVieClosed
Jun 4, 2018A 52-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic…RelamorelinAbbVieClosed
May 14, 2018A 46-week, double-blind, placebo-controlled, phase 3 study with a 6-week randomized-withdrawal period to evaluate the safety and efficacy of relamorelin in…RelamorelinAbbVieClosed
Dec 15, 2017A 12-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic…RelamorelinAbbVieClosed
Dec 4, 2013Prucalopride versus placebo in diabetic gastroparesis: randomized placebo-controlled crossover trialPrucaloprideUniversity of CalgaryClosed
Sep 11, 2013Nutritional adequacy therapeutic enhancement in the critically ill: a randomized double blind, placebo-controlled trial of the motilin receptor agonist…GSK962040GSKClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.